Table 4

Comparison of the baseline clinical and US variables between patients (with a follow-up of at least 3 months) without development of PsA and those developed PsA

PsO+PsOAr without PsA development (n=96)PsO+PsOAr with PsA development (n=6)P value
Age, mean (±SD)50.23 (±15.25)59.17 (±8.75)0.15
Female, n (%)54 (56.25 %)3 (50 %)1
Smoking, n (%)18 (18.75 %)0 (0 %)0.62
BMI, mean (±SD)25 (±4.29)28 (±3.16)0.08
Family history of PsA, n (%)14 (14.74 %)1 (16.67 %)1
VAS pain (0–10), mean (±SD)2.63 (±2.35)5.92 (±2.01)0.01
HAQ, mean (±SD)0.26 (±0.38)0.44 (±0.22)0.03
Tender joints count, mean (±SD)1.74 (±3.16)6.8 (±10.87)0.03
Tender enthesis count, mean (±SD)0.29 (±0.60)1 (±2.45)0.96
Active synovitis, n* (%)20 (20.83 %)2 (33.33 %)0.61
Active synovitis, mean joint number (±SD)0.3 (±0.68)1 (±1.67)0.31
Active enthesitis, n† (%)21 (21.88 %)4 (66.67 %)0.03
Active enthesitis, mean entheseal number (±SD)0.27 (±0.55)0.67 (±0.52)0.03
GS tenosynovitis, n‡ (%)19 (19.8%)1 (16.7%)1
GS tenosynovitis, mean (±SD)0.41 (1.07)0.25 (1.22)0.97
  • Values in bld signifies p value ≤0.05.

  • *Number of patients with at least one active synovitis.

  • †Active enthesitis.

  • ‡Tenosynovitis in GS.

  • BMI, body mass index; GS, grey scale; HAQ, Health Assessment Questionnaire; HC, healthy control; PsA, psoriatic arthritis; PsO, psoriasis alone; PsOAr, psoriasis patients with arthralgia; US, ultrasonography; VAS, Visual Analogue Scale.